BOM:509079 (India)
Â
Shs Dematerialised
₹
315.15
(+1.06%)
Jun 7
Business Description
Gufic Biosciences Ltd
ISIN : INE742B01025
Share Class Description:
BOM:509079: Shs DematerialisedCompare
Compare
Traded in other countries / regions
GUFICBIO.India IPO Date
2000-09-25Description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.63 | |||||
| Debt-to-EBITDA | 2.25 | |||||
| Interest Coverage | 8.37 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.69 | |||||
| Beneish M-Score | -1.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.6 | |||||
| 3-Year EBITDA Growth Rate | 19.3 | |||||
| 3-Year EPS without NRI Growth Rate | 24.2 | |||||
| 3-Year Book Growth Rate | 43.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.58 | |||||
| 9-Day RSI | 47.76 | |||||
| 14-Day RSI | 48.18 | |||||
| 6-1 Month Momentum % | -2.47 | |||||
| 12-1 Month Momentum % | 59.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.61 | |||||
| Quick Ratio | 1.08 | |||||
| Cash Ratio | 0.04 | |||||
| Days Inventory | 179.79 | |||||
| Days Sales Outstanding | 120.72 | |||||
| Days Payable | 140.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.03 | |||||
| Dividend Payout Ratio | 0.01 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Forward Dividend Yield % | 0.03 | |||||
| 5-Year Yield-on-Cost % | 0.07 | |||||
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -2.76 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.67 | |||||
| Operating Margin % | 15.93 | |||||
| Net Margin % | 10.68 | |||||
| FCF Margin % | -15.02 | |||||
| ROE % | 20.33 | |||||
| ROA % | 8.84 | |||||
| ROIC % | 12.04 | |||||
| ROC (Joel Greenblatt) % | 18.33 | |||||
| ROCE % | 20.86 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 37.42 | |||||
| PE Ratio without NRI | 37.42 | |||||
| Shiller PE Ratio | 62.87 | |||||
| PEG Ratio | 1.57 | |||||
| PS Ratio | 3.99 | |||||
| PB Ratio | 6.16 | |||||
| Price-to-Tangible-Book | 6 | |||||
| EV-to-EBIT | 26.54 | |||||
| EV-to-EBITDA | 23.5 | |||||
| EV-to-Revenue | 4.31 | |||||
| EV-to-FCF | -28.12 | |||||
| Price-to-DCF (Earnings Based) | 1.51 | |||||
| Price-to-Median-PS-Value | 1.73 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.61 | |||||
| Price-to-Graham-Number | 3.1 | |||||
| Price-to-Net-Current-Asset-Value | 78.01 | |||||
| Earnings Yield (Greenblatt) % | 3.77 | |||||
| FCF Yield % | -3.83 | |||||
| Forward Rate of Return (Yacktman) % | 18.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gufic Biosciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 8,066.657 | ||
| EPS (TTM) (₹) | 8.74 | ||
| Beta | 0.55 | ||
| Volatility % | 48.21 | ||
| 14-Day RSI | 48.18 | ||
| 14-Day ATR (₹) | 13.469546 | ||
| 20-Day SMA (₹) | 323.2475 | ||
| 12-1 Month Momentum % | 59.28 | ||
| 52-Week Range (₹) | 195.25 - 364 | ||
| Shares Outstanding (Mil) | 100.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gufic Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gufic Biosciences Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gufic Biosciences Ltd Frequently Asked Questions
What is Gufic Biosciences Ltd(BOM:509079)'s stock price today?
The current price of BOM:509079 is ₹315.15. The 52 week high of BOM:509079 is ₹364.00 and 52 week low is ₹195.25.
When is next earnings date of Gufic Biosciences Ltd(BOM:509079)?
The next earnings date of Gufic Biosciences Ltd(BOM:509079) is 2024-08-14 Est..
Does Gufic Biosciences Ltd(BOM:509079) pay dividends? If so, how much?
The Dividend Yield %  of Gufic Biosciences Ltd(BOM:509079) is 0.03% (As of Today), Highest Dividend Payout Ratio of Gufic Biosciences Ltd(BOM:509079) was 0.09. The lowest was 0.01. And the median was 0.02. The  Forward Dividend Yield % of Gufic Biosciences Ltd(BOM:509079) is 0.03%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers